Cyclerion Therapeutics Stock Analysis

Cyclerion Stock Analysis Notes

About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.83. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cyclerion Therapeutics recorded a loss per share of 4.29. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 16th of May 2023. Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system diseases. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Cyclerion Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people. For more info on Cyclerion Therapeutics please contact Peter Hecht at 857 327 8778 or go to https://www.cyclerion.com.

Cyclerion Therapeutics Investment Alerts

Cyclerion Therapeutics Upcoming and Recent Events

Cyclerion Largest EPS Surprises

View All Earnings Estimates

Cyclerion Therapeutics Environmental, Social, and Governance (ESG) Scores

Cyclerion Stock Institutional Investors

Note, although Cyclerion Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cyclerion Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.37 M.

Cyclerion Profitablity

Management Efficiency

Cyclerion Therapeutics has return on total asset (ROA) of (0.4655) % which means that it has lost $0.4655 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5025) %, meaning that it created substantial loss on money invested by shareholders. Cyclerion Therapeutics' management efficiency ratios could be used to measure how well Cyclerion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of September 2024, Return On Tangible Assets is likely to drop to -1.65. In addition to that, Return On Capital Employed is likely to grow to -0.81. At this time, Cyclerion Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 23rd of September 2024, Asset Turnover is likely to grow to 0.02, while Total Assets are likely to drop about 12.7 M.

Technical Drivers

As of the 23rd of September, Cyclerion Therapeutics shows the mean deviation of 6.96, and Risk Adjusted Performance of 0.0777. Cyclerion Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Cyclerion Therapeutics Price Movement Analysis

Cyclerion Therapeutics Insider Trading Activities

Cyclerion Therapeutics Outstanding Bonds

Cyclerion Therapeutics Predictive Daily Indicators

Cyclerion Therapeutics Corporate Filings

Cyclerion Therapeutics Forecast Models

Cyclerion Therapeutics' time-series forecasting models are one of many Cyclerion Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cyclerion Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cyclerion Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cyclerion shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cyclerion Therapeutics. By using and applying Cyclerion Stock analysis, traders can create a robust methodology for identifying Cyclerion entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cyclerion analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cyclerion analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Cyclerion Therapeutics stock analysis indicators help investors evaluate how Cyclerion Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cyclerion Therapeutics shares will generate the highest return on investment. By understating and applying Cyclerion Therapeutics stock analysis, traders can identify Cyclerion Therapeutics position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.